Aluminium lithium hydride → N-({4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]tetrahydro-2H-pyran-4-yl}methyl)ethanamine
반응식
[N:1]1([CH2:7][CH2:8][CH2:9][O:10][C:11]2[CH:16]=[CH:15][C:14]([C:17]3([CH2:23][NH:24][C:25](=O)[CH3:26])[CH2:22][CH2:21][O:20][CH2:19][CH2:18]3)=[CH:13][CH:12]=2)[CH2:6][CH2:5][S:4][CH2:3][CH2:2]1.[H-].[Al+3].[Li+].[H-].[H-].[H-]>>[N:1]1([CH2:7][CH2:8][CH2:9][O:10][C:11]2[CH:12]=[CH:13][C:14]([C:17]3([CH2:23][NH:24][CH2:25][CH3:26])[CH2:22][CH2:21][O:20][CH2:19][CH2:18]3)=[CH:15][CH:16]=2)[CH2:6][CH2:5][S:4][CH2:3][CH2:2]1참가 물질
3
실험 절차
The title compound (492 mg, 44%) was prepared using N-({4-[4-(3-thiomorpholin-4-ylpropoxy)phenyl]tetrahydro-2H-pyran-4-yl}methyl)acetamide and lithium aluminium hydride similarly to the procedure used for example 142. 1H NMR (400 MHz, CDCl3) δ 0.96 (t, 3H), 1.88-1.98 (m, 4H), 2.11-2.15 (m, 2H), 2.49 (q, 2H), 2.55 (t, 2H), 2.68-2.74 (m, 10H), 3.55 (t, 2H), 3.74-3.79 (m, 2H), 4.00 (t, 2H), 6.89 (d, 2H), 7.22 (d, 2H). LRMS APCI+ m/z 379 [MH]+.